Warning: The magic method WPML_Absolute_Url_Persisted::__wakeup() must have public visibility in /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php on line 30 Warning: The magic method Gallery_Video::__wakeup() must have public visibility in /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/gallery-video/video-gallery.php on line 72 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 Warning: Cannot modify header information - headers already sent by (output started at /customers/6/2/a/sosglobi.fr/httpd.www/wp-content/plugins/sitepress-multilingual-cms/classes/url-handling/resolver/wpml-absolute-url-persisted.php:30) in /customers/6/2/a/sosglobi.fr/httpd.www/wp-includes/rest-api/class-wp-rest-server.php on line 1893 {"id":3699,"date":"2022-02-21T12:59:26","date_gmt":"2022-02-21T11:59:26","guid":{"rendered":"https:\/\/sosglobi.fr\/?p=3699"},"modified":"2022-02-21T13:24:45","modified_gmt":"2022-02-21T12:24:45","slug":"oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe","status":"publish","type":"post","link":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/","title":{"rendered":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe!"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":3711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-3699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites"],"yoast_head":"\nOxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI<\/title>\n<meta name=\"description\" content=\"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI\" \/>\n<meta property=\"og:description\" content=\"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"SOS GLOBI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Federationsosglobi\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-21T11:59:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-21T12:24:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3456\" \/>\n\t<meta property=\"og:image:height\" content=\"1728\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sosglobi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:site\" content=\"@FMDTsosglobi\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sosglobi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\"},\"author\":{\"name\":\"Sosglobi\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\"},\"headline\":\"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe!\",\"datePublished\":\"2022-02-21T11:59:26+00:00\",\"dateModified\":\"2022-02-21T12:24:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\"},\"wordCount\":11,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\",\"url\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\",\"name\":\"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI\",\"isPartOf\":{\"@id\":\"https:\/\/sosglobi.fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png\",\"datePublished\":\"2022-02-21T11:59:26+00:00\",\"dateModified\":\"2022-02-21T12:24:45+00:00\",\"description\":\"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.\",\"breadcrumb\":{\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage\",\"url\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png\",\"contentUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png\",\"width\":3456,\"height\":1728},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/sosglobi.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/sosglobi.fr\/category\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sosglobi.fr\/#website\",\"url\":\"https:\/\/sosglobi.fr\/\",\"name\":\"SOS GLOBI\",\"description\":\"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie\",\"publisher\":{\"@id\":\"https:\/\/sosglobi.fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sosglobi.fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sosglobi.fr\/#organization\",\"name\":\"F\u00e9d\u00e9ration SOS GLOBI\",\"url\":\"https:\/\/sosglobi.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"contentUrl\":\"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png\",\"width\":242,\"height\":250,\"caption\":\"F\u00e9d\u00e9ration SOS GLOBI\"},\"image\":{\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Federationsosglobi\",\"https:\/\/x.com\/FMDTsosglobi\",\"https:\/\/www.instagram.com\/federation_sos_globi\/\",\"https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true\",\"https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c\",\"name\":\"Sosglobi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g\",\"caption\":\"Sosglobi\"},\"url\":\"https:\/\/sosglobi.fr\/author\/conectsosglbi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI","description":"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/","og_locale":"fr_FR","og_type":"article","og_title":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI","og_description":"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.","og_url":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/","og_site_name":"SOS GLOBI","article_publisher":"https:\/\/www.facebook.com\/Federationsosglobi","article_published_time":"2022-02-21T11:59:26+00:00","article_modified_time":"2022-02-21T12:24:45+00:00","og_image":[{"width":3456,"height":1728,"url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png","type":"image\/png"}],"author":"Sosglobi","twitter_card":"summary_large_image","twitter_creator":"@FMDTsosglobi","twitter_site":"@FMDTsosglobi","twitter_misc":{"\u00c9crit par":"Sosglobi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#article","isPartOf":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/"},"author":{"name":"Sosglobi","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c"},"headline":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe!","datePublished":"2022-02-21T11:59:26+00:00","dateModified":"2022-02-21T12:24:45+00:00","mainEntityOfPage":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/"},"wordCount":11,"commentCount":0,"publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"image":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/","url":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/","name":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe! - SOS GLOBI","isPartOf":{"@id":"https:\/\/sosglobi.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage"},"image":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png","datePublished":"2022-02-21T11:59:26+00:00","dateModified":"2022-02-21T12:24:45+00:00","description":"Ce 16 f\u00e9vrier 2022, la Commission Europ\u00e9enne a accord\u00e9 l'autorisation de mise sur le march\u00e9 d'Oxbryta (voxelotor), d\u00e9velopp\u00e9 par le laboratoire Global Blood Therapeutics (GBT), pour r\u00e9duire l'an\u00e9mie h\u00e9molytique chez les patients de 12 ans et plus atteints de dr\u00e9panocytose. Oxbryta est le 3\u00e8me m\u00e9dicament autoris\u00e9 en Europe dans la dr\u00e9panocytose, apr\u00e8s Siklos et Adakveo.","breadcrumb":{"@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#primaryimage","url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png","contentUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2022\/01\/Oxbryta-obtient-lAMM-Europe\u0301enne.png","width":3456,"height":1728},{"@type":"BreadcrumbList","@id":"https:\/\/sosglobi.fr\/actualites\/oxbryata-un-nouveau-traitement-de-la-drepanocytose-autorise-en-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/sosglobi.fr\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/sosglobi.fr\/category\/actualites\/"},{"@type":"ListItem","position":3,"name":"Oxbryta, un nouveau traitement de la dr\u00e9panocytose autoris\u00e9 en Europe!"}]},{"@type":"WebSite","@id":"https:\/\/sosglobi.fr\/#website","url":"https:\/\/sosglobi.fr\/","name":"SOS GLOBI","description":"Ensemble contre la dr\u00e9panocytose et la thalass\u00e9mie","publisher":{"@id":"https:\/\/sosglobi.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sosglobi.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/sosglobi.fr\/#organization","name":"F\u00e9d\u00e9ration SOS GLOBI","url":"https:\/\/sosglobi.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/","url":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","contentUrl":"https:\/\/sosglobi.fr\/wp-content\/uploads\/2021\/07\/cropped-logo2lignes.png","width":242,"height":250,"caption":"F\u00e9d\u00e9ration SOS GLOBI"},"image":{"@id":"https:\/\/sosglobi.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Federationsosglobi","https:\/\/x.com\/FMDTsosglobi","https:\/\/www.instagram.com\/federation_sos_globi\/","https:\/\/www.linkedin.com\/company\/sos-globi\/?viewAsMember=true","https:\/\/www.youtube.com\/channel\/UCftpQL09xzj4eqFLFZQmUNg"]},{"@type":"Person","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/8b233b80feabafb288e5c0d269a0465c","name":"Sosglobi","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/sosglobi.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0baf9e99b3c553dbb14a8ec7d51173b?s=96&d=mm&r=g","caption":"Sosglobi"},"url":"https:\/\/sosglobi.fr\/author\/conectsosglbi\/"}]}},"_links":{"self":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/3699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/comments?post=3699"}],"version-history":[{"count":7,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/3699\/revisions"}],"predecessor-version":[{"id":3782,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/posts\/3699\/revisions\/3782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media\/3711"}],"wp:attachment":[{"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/media?parent=3699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/categories?post=3699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sosglobi.fr\/wp-json\/wp\/v2\/tags?post=3699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}